Lung Therapeutics is a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. The Company is currently developing a drug technology, LTI-03, for the treatment of Idiopathic Pulmonary Fibrosis. Preclinical evidence suggests that LTI-03 sustains survival of damaged lung cells throughout this novel mechanism of action, in addition to slowing and resolving the downstream progress of fibrosis.
Lung Therapeutics total Funding
Lung Therapeutics latest funding size
Time since last funding
|a year ago|
Lung Therapeutics investors
|Bios Partners, Texas Venture Labs, UT Horizon Fund|
Lung Therapeutics has 264 Facebook Likes. The number of likes has increased 0.2% quarter over quarter